Publication number: 20140220011
Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, ClORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and ClORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.
Type:
Application
Filed:
February 15, 2013
Publication date:
August 7, 2014
Applicant:
COMPUGEN LTD.
Inventors:
Amir TOPORIK, Amit NOVIK, Anat COHEN-DAYAG, Avi Yeshah ROSENBERG, Cynthia KOIFMAN, Dalit LANDESMAN-MILO, Eve MONTIA, Galit ROTMAN, Liat DASSA, Marina BUBIS, Merav BEIMAN, Ofer LEVY, Sergey NEMZER, Tania PERGAM, Yaron KINAR, Shirley SAMEACH-GREENWALD, Zurit LEVINE, Shira WALACH
Patent number: 8415455
Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.
Type:
Grant
Filed:
September 3, 2008
Date of Patent:
April 9, 2013
Assignee:
Compugen Ltd
Inventors:
Zurit Levine, Tania Pergam, Dalit Landesman-Milo, Anat Cohen-Dayag, Amir Toporik, Yaron Kinar, Sergey Nemzer, Avi Rosenberg, Galit Rotman, Amit Novik, Cynthia Koifman, Merav Beiman, Liat Dassa, Shira Walach, Eve Montia, Shirley Sameach-Greenwald, Ofer Levy, Marina Bubis
Publication number: 20120134997
Abstract: This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development.
Type:
Application
Filed:
September 3, 2008
Publication date:
May 31, 2012
Applicant:
COMPUGEN LTD.
Inventors:
Zurit Levine, Tania Pergam, Dalit Milo, Anat Cohen-Dayag, Amir Toporik, Yaron Kinar, Sergey Nemzer, Avi Rosenberg, Galit Rotman, Amit Novik, Cynthia Koifman, Merav Beiman, Liat Dassa, Shira Walach, Eve Montia, Shirley Sameach-Greenwald, Oler Levy, Marina Bubis